Cargando…
Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer
SIMPLE SUMMARY: Around thirty-five percent of pancreatic cancer patients present with locally advanced pancreatic cancer. These patients are treated with chemotherapy, and sometimes (stereotactic)radiotherapy can be added to the treatment regimen. In this study, we treated patients with locally adva...
Autores principales: | van ‘t Land, Freek R., Lau, Sai P., de Koning, Willem, Klaase, Larissa, Vink, Madelief, van Krimpen, Anneloes, Dumas, Jasper, Vadgama, Disha, Nuyttens, Joost J., Mustafa, Dana A. M., Stadhouders, Ralph, Willemsen, Marcella, Stubbs, Andrew P., Aerts, Joachim G., van Eijck, Casper H. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656492/ https://www.ncbi.nlm.nih.gov/pubmed/36358718 http://dx.doi.org/10.3390/cancers14215299 |
Ejemplares similares
-
Mycobacterium obuense Bacteremia in a Patient with Pneumonia
por: Luis, Bruno Ali López, et al.
Publicado: (2019) -
IMM-101, an immunotherapeutic agent in clinical development as an adjunctive treatment for pancreatic cancer
por: Bilyard, Hilary, et al.
Publicado: (2014) -
Suppression of the malignancy of mammary tumor in mice model by inactivated preparation of Mycobacterium obuense
por: Nofouzi, Katayoon, et al.
Publicado: (2022) -
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
por: Dalgleish, Angus G, et al.
Publicado: (2016) -
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
por: Dalgleish, Angus G, et al.
Publicado: (2016)